Rahul Banarjee, Assistant Professor in the Division of Medical Oncology at the University of Washington, recently shared on X:
“Now out! Updated data for eque-cel (CT103A), fully human BCMA CAR-T in myeloma.
ORR 96% (n=103), 2-yr PFS > 60%, comparatively few ADAs!
BCMA expression required to enter trial, so ORR won’t always be 75% if BCMA-exposed.
14% TRM, mainly infections but 2 Gr5 CRS.”
